Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector
2006 StandoutNobel
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Development of Serotonin Antagonists for the Control of Chemotherapy‐Induced Emesis
1993
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
1999 Standout
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
2006
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group
2004
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Testicular Germ-Cell Cancer
1997 Standout
Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy
1996
The Nottingham prognostic index in primary breast cancer
1992
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents
1997
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
1998
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
1991
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting
2000
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Paclitaxel (Taxol)
1995 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy
1995
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
1994
Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic Chemotherapy
1993
The efficacy of a combination of ondansetron, methyiprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy
1997
Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy
2002
Current Management Strategies for Ovarian Cancer
2007
A phase II study
2000
Immunocytochemical Analysis of Estrogen Receptors in Human Breast Carcinomas
1990
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Pathological prognostic factors in breast cancer
1999 Standout
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
1996
Tissue microarrays for high-throughput molecular profiling of tumor specimens
1998 Standout
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
2001 StandoutNobel
Methodological issues in antiemetic studies
1993
Cellular processing of platinum anticancer drugs
2005 Standout
Drug Treatment of Chemotherapy-Induced Delayed Emesis
1996
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
1996
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
1999
Collective cell migration in morphogenesis, regeneration and cancer
2009 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Serotonin receptors: Subtypes, functional responses and therapeutic relevance
1995
Dermal Lymphatic Emboli in Inflammatory and Noninflammatory Breast Cancer: A French-Tunisian Joint Study in 337 Patients
2005
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study
2000
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Is there a Reliable Method to Assess the Complete Pathologic Response on the Tumor after Neo-adjuvant Chemotherapy in Inflammatory Breast Cancer toward Recommendations for the Pathologic Process? Experience in 56 Patients Treated in a Single Institution
2010
Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production
2008 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis
1994
Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review
2002
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer
2012
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Preservation of Fertility in Patients with Cancer
2009 Standout
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
2003
Anemia of Chronic Disease
2005 Standout
Breast cancer metastasis: markers and models
2005 Standout
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
2002
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Cancer of the Ovary
2004 Standout
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
2001
Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy—A Phase II Single-Center Study
1999
The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
2001
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
1999
Current Management Strategies for Ovarian Cancer
2007
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
2006
Inactivation of a Serotonin-Gated Ion Channel by a Polypeptide Toxin from Marine Snails
1998 StandoutScienceNobel
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.
2001
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy.
1987
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
2003
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin.
2008
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
2014
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
1995
Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study
2001
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for Cancer
1995
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
2000
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
CNS Metastases in Breast Cancer
2004
Works of B Chevallier being referenced
Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.
1992
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
1998
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
1995
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC
1996
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
1990
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy
1997
Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer
1990
The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients
1993
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
1995
Early Intensified Chemotherapywith AutologousBone Marrow Transplantation inFirst Line Treatment ofPoor Risk Non-SeminomatousGerm Cell Tumours
1993
Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
1989
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
1995
A prognostic score in histological node negative breast cancer
1990
Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5-HT3 Antagonist, in Cancer Patients Treated with Cisplatin
1994
The control of acute cisplatin-induced emesis – a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone
1993
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC
1996
Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles
1994
Pirarubicin in advanced breast cancer: A French Cooperative phase II study
1990
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: Study of the clinical screening group of the European Organization for Research and Treatment of Cancer (EORTC)
1993
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
1993
Prognostic value of estrogen and progesterone receptors in operable breast cancer
1987
High-dose intensity regimens with epirubicin in ovarian cancer.
1994
Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)
1997
Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
1990
High dose chemotherapy in ovarian carcinoma
1993